JJ Park, H Kim, YK Kim, SS Lee, E Jung… - Journal of Korean …, 2023 - ncbi.nlm.nih.gov
Background In this study, we aimed to compare the effectiveness and adverse reactions of nirmatrelvir/ritonavir and molnupiravir in high-risk outpatients with coronavirus disease 2019 …
TK Patel, PB Patel, M Barvaliya, MK Saurabh… - Journal of infection and …, 2021 - Elsevier
Background Lopinavir-ritonavir is a repurposed drug for coronavirus disease-2019 (COVID- 19). In this study, a pooled effect of lopinavir-ritonavir on mortality, virological cure …
LA Nicolini, M Mikulska, A Signori… - Open Forum …, 2020 - academic.oup.com
2. Li Y, Xie Z, Lin W, et al. An exploratory randomized controlled study on the efficacy and safety of lopinavir/ritonavir or arbidol treating adult patients hospitalized with mild/moderate …